Company intelligence / Profile preview

SEQENS

Ownership: Private
Employees: ~3300
Development stage: Commercial

Overview

SEQENS is an integrated global leader in pharmaceutical solutions, specializing in the development, scale-up, and commercial manufacturing of active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, polymers for drug delivery/RNA encapsulation/medical devices, and biotechnological products. The company serves over 1,500 customers worldwide with end-to-end support from R&D through industrialization.

Modalities: Small moleculeSynthetic polymerBiologicEnzyme replacement therapyPeptides
Industry: Drug Discovery Services

Drug pipeline

1 asset

propofol

Commercial

Indications: General anesthesia, Sedation

Partnerships

Works with over 1500 customers globally including major pharma/biotech companies

Beyond the preview

Go deeper on SEQENS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEQENS.

Explore the full profile